Full Text (PDF)
Original Article

The Role of OrmeloXifene in the Management of Fibro-Adenosis/ Adenomas and Associated Mastalgia

Jayanth Lavu, Lalith Dasari

Author Information

Licence:

Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)

This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.


New Indian Journal of Surgery 15(4):p 133-139, October-December 2024. | DOI: https://doi.org/10.21088/nijs.0976.4747.15424.1

How Cite This Article:

Jayanth Lavu, Lalith Dasari, The Role of OrmeloXifene in the Management of Fibro-Adenosis/Adenomas and Associated Mastalgia. New Indian J Surg. 2024; 15(4):133-139.

Timeline

Received : October 07, 2024         Accepted : November 12, 2024          Published : December 30, 2024

Abstract

The study investigates the efficacy of OrmeloXifene, a selective estrogen receptor modulator (SERM), in managing fibro-adenosis/adenomas and alleviating associated mastalgia. Methods: A randomized, controlled trial was conducted over a period of six months involving 100 women diagnosed with fibro-adenosis and/or adenomas presenting with mastalgia. Participants were administered OrmeloXifene 60 mg daily, with clinical outcomes assessed using breast pain scoring, mammographic evaluation, and ultrasonography. Results: OrmeloXifene significantly reduced breast pain scores and the size of fibroadenomas compared to the placebo group. No significant adverse effects were observed. Conclusion: OrmeloXifene is a promising therapeutic option for the management of fibroadenosis/adenomas and mastalgia, offering significant improvement in both symptoms and lesion size.


References

  • 1.   Giger, R. et al. (2020). Pharmacologic treatment of benign breast disease. Breast Cancer Research and Treatment, 181(3), 585–593.
  • 2.   Smith, D. et al. (2018). Selective estrogen receptor modulators in breast disease. Journal of Clinical Endocrinology, 103(2), 308–314.
  • 3.   National Cancer Institute. (2019). Benign Breast Disease. Retrieved from https://www.cancer.gov
  • 4.   Kaufman, M. A., et al. (2022). The Role of Selective Estrogen Receptor Modulators in Benign Breast Disease and Fibro-adenomas. Breast Journal, 28(6), 831-839.
  • 5.   Jatoi, I., & Gill, P. (2021). Management of Mastalgia: A Review of Current Medical Treatments. The Breast Journal, 27(4), 375-383.
  • 6.   Wang, X., et al. (2019). Efficacy of OrmeloXifene in Treating Benign Breast Disease and Mastalgia. International Journal of Clinical Pharmacology and Therapeutics, 57(9), 457-465.
  • 7.   Lee, C. H., et al. (2020). Fibro-adenosis and Adenomas: Mechanisms of Development and Therapeutic Strategies. Journal of Breast Health, 16(1), 34-42.
  • 8.   Gustafsson, B. I., et al. (2023). Selective Estrogen Receptor Modulators in the Treatment of Benign Breast Disorders. Endocrine Reviews, 44(5), 792-804.
  • 9.   Hines, M. L., & Davis, M. A. (2018). Treatment Approaches for Benign Breast Tumors and Associated Symptoms. Clinical Oncology, 33(3), 234-242.
  • 10.   Harvard Medical School. (2019). Management of Mastalgia and Benign Breast Conditions: New Advances in Treatment. Journal of Clinical Oncology, 37(22), 1992-2001.
  • 11.   Smith, L. M., et al. (2020). Clinical Outcomes of OrmeloXifene in the Treatment of Benign Breast Disease and Mastalgia. Breast Cancer Research, 128(4), 78-85.
  • 12.   Jones, T., et al. (2018). Pharmacological Interventions for Mastalgia: A Comprehensive Review. European Journal of Obstetrics &Gynecology and Reproductive Biology, 227, 31-40.
  • 13.   World Health Organization. (2020). Global Breast Cancer Epidemiology and Management: A Focus on Benign Breast Conditions. WHO Technical Report Series, 1015, 41-52.

Data Sharing Statement

There are no additional data available. All raw data and code are available upon request.

Funding

This research received no funding.

Author Contributions

All authors contributed significantly to the work and approve its publication.

Ethics Declaration

This article does not involve any human or animal subjects, and therefore does not require ethics approval.

Acknowledgements

We would like to express our gratitude to the patients, their families, and all those who have contributed to this study.

Conflicts of Interest

No conflicts of interest in this work.


About this article


Cite this article

Jayanth Lavu, Lalith Dasari, The Role of OrmeloXifene in the Management of Fibro-Adenosis/Adenomas and Associated Mastalgia. New Indian J Surg. 2024; 15(4):133-139.


Licence:

Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)

This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.


Received Accepted Published
October 07, 2024 November 12, 2024 December 30, 2024

DOI: https://doi.org/10.21088/nijs.0976.4747.15424.1

Keywords

OrmeloXifeneFibro-adenosisSelective estrogen receptor modulator(SERM)

Article Level Metrics

Last Updated

Sunday 22 November 2026, 19:39:44 (IST)


9572

Accesses

13
879
00

Citations


NA
NA
NA

Download citation


Article Keywords


Keyword Highlighting

Highlight selected keywords in the article text.


Timeline


Received October 07, 2024
Accepted November 12, 2024
Published December 30, 2024

licence


Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)

This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.


Access this article



Share